Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells
Recruiting now · Not applicable
Conditions studied: Malignant Hemopathy
In brief
Chemotherapy or targeted therapy are usually used to treat hematological pathologies. Despite of medical improvement, some of these pathologies present drug resistances, or high risk of relapse. Hematopoietic stem cell (HSC) transplantation remain the gold standard of consolidation, to maintain a durable response. In this situation, allograft with hematopoietic stem cells donor aims at producing Graft-versus-Tumor effect, by producing a new immune system, reproducing anti-tumoral immunity. However, all hemopathies do not have the same sensibility. Nowadays, mechanisms underlying this phenomenon remain poorly understood. Indeed, few data precisely document the expression of immunological checkpoints and other biomarkers in the context of allogeneic HSC transplantation, particularly their impact on post-transplant outcome.
Key facts
- Study ID
- NCT04517656
- Run by
- Centre Hospitalier Universitaire de Saint Etienne
- People needed
- 40
- Starts
- 2022-05-25
- Expected to finish
- 2026-09-30
- Last updated by the study team
- 2025-04-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult patient, over 18 years of age, suffering from a malignant hemopathy (without exception),
- Patient for whom an allogeneic hematopoietic stem cell transplant from a related or unrelated donor is indicated,
- Signed informed consent,
- Patient covered by a social security scheme.
You may not qualify if…
- Allogeneic hematopoietic stem cell transplantation from cord blood or haplo-identical transplant,
- Allogeneic transplant with post-transplant cyclophosphamide treatment,
- Allograft with sequential conditioning.
Where it is running
- CHU de Saint-Etienne — Saint-Etienne, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.